Guillevin L, Euller-Ziegler L, Chouvet B, De Gery A, Chassoux G, Lafay P, Ziegler G, Godeau P, Amor B, Thivolet J
Presse Med. 1985 Dec 28;14(46):2327-9.
Eighty-six patients with progressive systemic sclerosis were given coagulation factor XIII intravenously in different dosage regimens. The mean duration of treatment was 19 +/- 18 months and patients were followed up for 22.9 +/- 18.8 months. Improvement or stabilization of the lesions was obtained in 44/86 patients and exclusively concerned skin lesions; there was no improvement in visceral lesions. The drug was well tolerated in short-and long-term treatment. It is concluded that factor XIII demonstrated lasting effectiveness in one-half of the patients treated.
86例进行性系统性硬化症患者接受了不同剂量方案的静脉注射凝血因子XIII治疗。平均治疗时长为19±18个月,患者随访时间为22.9±18.8个月。86例患者中有44例病变得到改善或稳定,且仅涉及皮肤病变;内脏病变无改善。该药物在短期和长期治疗中耐受性良好。结论是,凝血因子XIII在一半接受治疗的患者中显示出持久疗效。